Medscape13h
Pirtobrutinib’s Star Turn in Relapsed/Refractory CLL May Get an Encore
In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...
Man’s chemo journey to take centre stage at Belfast festival: ‘I found a richer version of myself’
An Enniskillen-based man will this week share his chemotherapy journey in a festival performance to raise funds for cancer ...
‘I found a richer version of myself’: Man’s chemo journey to take centre stage at Belfast festival
An Enniskillen-based man will this week share his chemotherapy journey in a festival performance to raise funds for cancer ...
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
Targeted Oncology4d
Jurczak on BTK Inhibitors and the Future of B-Cell Lymphoma Therapy
Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...
IndiaInfoline4d
Biocon Pharma Gains USFDA Approval for Norepinephrine and Key Therapies
This approval augments Biocon Pharma's complex injectables portfolio and reinforces its footprint in the US pharma market.
Targeted Oncology6d
The Evolution of BTK Inhibitors in B-Cell Lymphoma
Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.